CRISPR and CAS Gene Market Set for Rapid Growth And Trend by 2026

CRISPR and CAS Gene Market Set for Rapid
Growth And Trend by 2026
CRISPR and CAS Gene Market, By Product Type (Vector-based Cas and DNA-free
Cas), By Application (Genome Engineering, Disease models, Functional
Genomics, Knockdown/activation and Other Applications), By End User
(Biotechnology and Pharmaceutical Companies, Academic Government
Research Institutes, and Contract Research Organizations), and By Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
The CRISPR and CAS Gene Market size was valued at US$ 1,388.1 million in 2017, and is
expected to witness a CAGR of 20.8% over the forecast period (2018 – 2026). CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential for
the adaptive immunity in few bacteria and archaea, enabling the organisms to respond to and to
eliminate invading genetic material. These gene editing tools are extensively used in agriculture and
food security.
Many food and agricultural organizations are working on receiving license for using CRISPR and CAS
gene technology for creating novel products in food and agriculture business. For instance, in
September 2016, agrochemical and agricultural biotechnology corporation Monsanto secured a
worldwide non-exclusive license agreement for agricultural applications of CRISPR technology from
the Broad Institute. CRISPR and CAS genes are also used in treating a number of diseases such as
cancer, blood disorders, AIDS, and genetic disorders such as cystic fibrosis, Huntington’s etc.
Market Dynamics
Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and
Huntington’s disease worldwide is highly contributing to the market growth of CRISPR and CAS gene
market, as many genetic disabilities can be corrected using this gene editing technology. According to
National Health Service (NHS) U.K. 2018 report, the highest rate of Huntington’s disease in the United
Kingdom is 12 per 100,000 people.
Government bodies are taking initiatives for developing treatment of Huntington’s disease. For
instance, in 2016, US-based Company Addgene has developed the KamiCas9, a version of CRISPRCas9 that includes a ‘self-inactivating’ KamiCas9 system for the editing of CNS disease genes for
treatment of Huntington’s disease.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2598
Increasing Demand for Clinical Trials Coupled with Increasing Research & Development in
CRISPR and CAS Gene therapy is expected to Drive Growth of the CRISPR and CAS Gene
Market
Increasing research & development and demand for clinical trials for development of new technologies
in CRISPR and CAS gene therapy for treatment of cancer is one of the major driving factor. For
instance, The Parker Institute for Cancer Immunotherapy, a non-profit organization formed in April
2016, with a US$ 250 million grant from the Parker Foundation, agreed to sponsor the first in-human
clinical trials of CRISPR-enabled technology targeting three types of cancer. The trial, led by the
University of Pennsylvania, will use CRISPR-modified T-cells, a part of the human immune system, to
treat myeloma, melanoma, and sarcoma. The trial was commenced in 2017.
CRISPR and CAS Gene Market - Competitive Landscape
Key players operating in the global CRISPR and CAS Gene market include Caribou Biosciences Inc.,
CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher
Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies,
Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs,
Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.
CRISPR and CAS Gene Market - Regional Insights
On the basis of region, the global CRISPR and CAS Gene market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a
dominant position in the global CRISPR and CAS Gene market, owing to increasing number of the
Food and Drug Administration (FDA) approval for clinical trial.
Asia Pacific is expected to foresee a rapid growth in the CRISPR and CAS Gene market over the
forecast period. The market in Asia Pacific is expected to gain momentum during the forecast period,
owing to rise in the demand of CRISPR and CAS gene therapy especially in research activities. For
instance, in May 2018 researchers at Kobe University in Japan successfully destroyed and deleted the
regulatory genes of HIV-1 using the genome editing system CRISPR/Cas9, thereby successfully
blocking the production of HIV-1 by infected cells.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

The CRISPR and CAS Gene Market size was valued at US$ 1,388.1 million in 2017, and is expected to witness a CAGR of 20.8% over the forecast period (2018 – 2026).

Download Report